Tuesday 13 October 2026
Export ALT’s income statement to Excel — free account
Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.46
0.10
−3.91%
Follow ALT
Altimmune, Inc. (ALT) P/E ratio
Altimmune, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.8× (December 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 40 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.8×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PROK ProKidney Corp. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| ALT Altimmune, Inc. | n/m |
| OCS Oculis Holding AG compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ARVN Arvinas, Inc. compare | 57.3× |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)